Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Anemia, Sickle Cell

• A Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell Disease
• Realizing Effectiveness Across Continents With Hydroxyurea
• Non-myeloablative Haploidentical HCT Study for Patients With Sickle Cell Disease, Including Compromised Organ Function
• A Safety, Efficacy, and Pharmacokinetic (PK) Study of HBI-002, an Oral Carbon Monoxide (CO) Therapeutic, in Subjects With Sickle Cell Disease (SCD)
• Siplizumab for Sickle Cell Disease Transplant
• Alendronate for Osteonecrosis in Adults With Sickle Cell Disease
• Voxelotor CYP and Transporter Cocktail Interaction Study
• A Phase 2 Open-label Study to Evaluate the Activity of Etavopivat on Transcranial Doppler Velocities in Pediatric Patients With Sickle Cell Disease Who Are at Increased Risk for Primary Stroke
• Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease
• Pharmacokinetics, Pharmacodynamics and Safety of Epeleuton in Patients With Sickle Cell Disease
• Clonidine With Morphine in Patient Controlled Analgesia Pump in Vaso-Occlusive Crisis in Sickle Cell Disease Patient
• A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)
• Effects of the Contraceptive Implant in Women With Sickle Cell Disease
• Study of the Effect of Etavopivat on Cerebral Hemodynamic Response in Children With Sickle Cell Disease
• A GBT021601 ADME Microtracer Study in Healthy Volunteers
• Hydroxyurea Treatment for Adult Sickle Cell Anemia Patients in Kinshasa
• Alternative Dosing And Prevention of Transfusions (ADAPT)
• A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Oral GSK4172239D Compared With Placebo in Sickle Cell Disease Participants Aged 18 to 50 Years
• Tocilizumab Acute Chest
• GBT021601-022: A Study of GBT021601 in Participants With Sickle Cell Disease (SCD)
• Motixafortide and Natalizumab to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD)
• Minocycline In Neurocognitive Outcomes - Sickle Cell Disease
• Relationship Between Abnormal Myocardial Perfusion and Diastolic Dysfunction in Sickle Cell Disease Using PET
• Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Study of ALXN1820 in Adult Participants With Sickle Cell Disease
• Resolution of Sickle Cell Leg Ulcers With Voxelotor
• Cannabinoids for the Reduction of Inflammation and Sickle Cell Related Pain
• L-Arginine in Children Having Sickle Cell Disease With Increased Tricuspid Regurgitant Jet Velocity
• Acceptability of a New Paediatric Formulation of Hydroxycarbamide in Children With Sickle Cell Disease.
• Crizanlizumab Improves Tissue Oxygen Supply Demand Matching in Patients With Sickle Cell Anemia
• Hydroxyurea and EPO in Sickle Cell Disease
• Study of MGTA-145 and Plerixafor in Patients With Sickle Cell Disease
• Primary Prevention of Stroke in Children With Sickle Cell Anaemia in Nigeria in the Community
• A Phase 2/3 Study in Adult and Pediatric Participants With Sickle Cell Disease (SCD)
• Research Study Investigating How Well NDec Works in People With Sickle Cell Disease
• Low Dose Iron Chelation as TReatment of Oxidative Damage in Sickle Cell Disease
• TMLI and Alemtuzumab for Treatment of Sickle Cell Disease
• Glutamine Role in Preventing Vaso-occlusive Crisis Among SCD Patients
• Addition of JSP191 (C-kit Antibody) to Non-myeloablative Hematopoietic Cell Transplantation For Sickle Cell Disease and Beta-Thalassemia
• A Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease
• Promoting Utilization and Safety of Hydroxyurea Using Precision in Africa
• A Phase 1/2, Open-Label, Dose Escalating Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AB1 in Adult Patients With Sickle Cell Disease (SCD)
• Low Dose Aspirin for Preventing Intrauterine Growth Restriction and Preeclampsia in Sickle Cell Pregnancy (PIPSICKLE)
• Voxelotor Neurocognitive Function Study
• Voxelotor Cerebral Hemodynamics Study
• Preservation and Transfer of HBV Immunity After Allogeneic HSCT for SCD.
• Hemolysis Related Complications in SCD. A Phase II Study With Voxelotor
• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of FTX-6058
• A Randomized Controlled Double-Blind Trial for Prevention of Recurrent Ischemic Priapism in Men With Sickle Cell Disease: A Pilot Study
• Pharmacokinetics and Pharmacodynamics of Rifaximin Novel Formulations in Patients With Sickle Cell Disease
• Interest of Famotidine in Children With Sickle Cell Disease
• Hydoxycarbamide and L-Carnitine Therapy in Sickle Cell Anemia
• A Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab as Adjunct Treatment in Prevention of Vaso-Occlusive Episodes (VOE) in Sickle Cell Disease (SCD)
• A Study to Evaluate GBT021601 in Single and Multiple Doses in Healthy Participants
• THromboprophylaxis In Sickle Cell Disease With Central Venous Catheters (THIS)
• A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease
• The Effect of Voxelotor on Cerebral Hemodynamic Response in Children With Sickle Cell Anemia
• Losartan for Diffuse Myocardial Fibrosis in Sickle Cell Disease
• A Study of FT-4202 in Patients With Thalassemia or Sickle Cell Disease
• A Study to Evaluate GBT021601-012 Single Dose and Multiple Dose in Participants With Sickle Cell Disease (SCD)
• A Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises
• A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises
• PET Imaging of Vaso-Occlusive (VOC) in SCD
• A Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Crovalimab for the Management of Acute Uncomplicated Vaso-Occlusive Episodes (VOE) in Participants With Sickle Cell Disease (SCD).
• L-citrulline Injection in Patients Aged 6-21 Years Old With Sickle Cell Disease Presenting With Vaso-Occlusive Crisis (VOC)
• Dihydroartemisinin-Piperaquine or Sulphadoxine-Pyrimethamine for the Chemoprevention of Malaria in Sickle Cell Anaemia
• Sickle Cell Disease Treatment With Arginine Therapy (STArT) Trial
• Study to Assess Efficacy and Safety of VIT-2763 in Subjects With Sickle Cell Disease
• Peripheral Blood Stem Cell Collection From Patients With Sickle Cell Disease (SCD) Using Plerixafor
• Pre-transplant Immunosuppression and Donor Stem Cell Transplant for the Treatment of Severe Hemoglobinopathies
• Transplantation of Clustered Regularly Interspaced Short Palindromic Repeats Modified Hematopoietic Progenitor Stem Cells (CRISPR_SCD001) in Patients With Severe Sickle Cell Disease
• Hydroxyurea Therapy for Neurological and Cognitive Protection in Pediatric Sickle Cell Anemia in Uganda ( BRAINSAFE-II )
• Pharmacokinetics and Safety of Endari (L-glutamine) in Sickle Cell Disease Patients
• An Indian Multi-centric Phase IV Study to Assess the Safety of Crizanlizumab in Sickle Cell Disease Patients
• Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study
• A Study of FT-4202 in Adults and Adolescents With Sickle Cell Disease (HIBISCUS)
• Lidocaine Intravenous in the Emergency Department For Sickle Cell Crisis
• Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Long-term Mitapivat Dosing in Subjects With Stable Sickle Cell Disease: An Extension of a Phase I Pilot Study of Mitapivat
• Voxelotor Sickle Cell Exercise Study
• A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunteers and in Participants With Sickle Cell Disease
• Fixed Dose Flavonoid Isoquercetin on Thrombo-Inflammatory Biomarkers in Subjects With Stable Sickle Cell Disease
• Red Cell Half Life Determination in Patients With and Without Sickle Cell Disease
• Isoquercetin in Sickle Cell Anemia
• A Study of IMR-687 in Subjects With Sickle Cell Disease
• The BENeFiTS Trial in Beta Thalassemia Intermedia
• Red Blood Cell Survival in Sickle Cell Disease
• Desmopressin for Bedwetting in Children With SCD
• Metabolic and Hemodynamic Reserve in Pediatric SCA
• Actigraphy Improvement With Voxelotor (ActIVe) Study
• Reduced Intensity Transplantation for Severe Sickle Cell Disease
• SMILES: Study of Montelukast in Sickle Cell Disease
• A Voxelotor for Sickle Cell Anemia Patients at Highest Risk for Progression of Chronic Kidney Disease
• Different Treatment Modalities in the Management of the Painful Crisis in Pediatric Sickle- Cell Anemia
• Study to Evaluate the Effect of Ticagrelor Versus Placebo in Reducing Vaso-Occlusive Crises Rate in Pediatric Patients With Sickle Cell Disease.
• Dose Escalation Study to Evaluate the Safety, Tolerability, PK and PD of Voxelotor in Patients With SCD
• Study to Evaluate the Effect of GBT440 on TCD in Pediatrics With Sickle Cell Disease
• Pediatric Open-Label Extension of Voxelotor
• Daily Vitamin D for Sickle-cell Respiratory Complications
• Intranasal Ketamine For Pain Control In Patients With Sickle Cell Disease And Vaso-occlusive Episode (VOE) In The PED
• AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion
• Deferoxamine for Sickle Cell Chronic Leg Ulcer Treatment
• A Study of Nicotinamide With Oral Tetrahydrouridine and Decitabine to Treat High Risk Sickle Cell Disease
• An Extension Study of IMR-687 in Adult Patients With Sickle Cell Anemia
• Study Exploring the Effect of Crizanlizumab on Kidney Function in Patients With Chronic Kidney Disease Caused by Sickle Cell Disease
• Early Human Leukocyte Antigen (HLA) Matched Sibling Hematopoietic Stem Cell Transplantation
• Ketamine Infusion for Sickle Cell Pain Crisis
• Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Escalating Multiple Oral Doses of AG-348 in Subjects With Stable Sickle Cell Disease
• Imatinib for Pain in Sickle Cell Anemia
• A Study of SHP655 (rADAMTS13) in Sickle Cell Disease
• Dronabinol for Pain and Inflammation in Adults Living With Sickle Cell Disease
• Stroke Prevention With Hydroxyurea Enabled Through Research and Education (SPHERE)
• Outcomes Mandate National Integration With Cannabis as Medicine for Prevention and Treatment of COVID-19
• A Study to Evaluate the Safety and Efficacy of Crizanlizumab in Sickle Cell Disease Related Priapism
• Comparing Individualized vs. Weight Based Protocols to Treat VOE in SCD Occlusive Episodes in Sickle Cell Disease
• A Study to Assess the Safety and Pharmacokinetics of HBI-002, an Oral Carbon Monoxide Therapeutic, in Healthy Volunteers
• Endothelial Monocyte-activating Polypeptide-II in Egyptian Sickle Patients
• Sickle Cell Pain: Intervention With Capsaicin Exposure
• Hydroxyurea Therapy: Optimizing Access in Pediatric Populations Everywhere
• A SAD/MAD to Assess the Safety, Pharmacokinetics and Pharmacodynamics of FT-4202 in Healthy Volunteers and Sickle Cell Disease Patients
• Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients
• SIKAMIC (SIklos on Kidney Function and AlbuMInuria Clinical Trial)
• Defibrotide in Sickle Cell Disease-Related Acute Chest Syndrome
• Hydroxyurea Optimization Through Precision Study
• Pharmacokinetics of Oral Hydroxyurea Solution
• Inhaled Mometasone to Promote Reduction in Vasoocclusive Events 2
• Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study
• Rifaximin to Modify the Disease Course in Sickle Cell Disease
• Safety of Blood Stem Cell Mobilization With Plerixafor in Patients With Sickle Cell Disease
• T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias
• A Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell Disease
• Hydroxyurea and Transfusion
• Management of Severe Acute Malnutrition in SCD, in Northern Nigeria
• Effect of Ticagrelor vs. Placebo in the Reduction of Vaso-occlusive Crises in Pediatric Patients With Sickle Cell Disease
• Central Nervous System Vascular Changes in Adult Sickle Cell Disease and the Effect of Treatment With Simvastatin
• Minimizing Toxicity in HLA-identical Related Donor Transplantation for Children With Sickle Cell Disease
• Study to Assess the Effect of Long-term Treatment With Voxelotor in Participants Who Have Completed Treatment in Study GBT440-031
• Does IV Acetaminophen Reduce Opioid Requirement in Pediatric Patients With Acute Sickle Cell Crises?
• Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation
• PK Study of Ticagrelor in Children Aged Less Than 24 Months, With Sickle Cell Disease (HESTIA4)
• Assessing the Safety of Buprenorphine in People With Sickle Cell Disease
• Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients
• Ketamine for Acute Painful Crisis in Sickle Cell Disease Patients
• Stem Cell Transplant in Patients With Severe Sickle Cell Disease
• A Study of IMR-687 in Adult Patients With Sickle Cell Anaemia (Homozygous HbSS or Sickle-β0 Thalassemia)
• Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer
• Adjuvant Low-dose Ketamine in Pediatric Sickle Cell Vaso-occlusive Crisis
• Zinc Supplementation in Children With Sickle Cell Disease in Western Kenya
• A Study of the Effect of IW-1701 (Olinciguat), a Stimulator of Soluble Guanylate Cyclase (sGC), on Patients With Sickle Cell Disease (SCD)
• Pharmacokinetics and Pharmacodynamics Study of SEG101 (Crizanlizumab) in Sickle Cell Disease (SCD) Patients With Vaso- Occlusive Crisis (VOC)
• Haploidentical Bone Marrow Transplantation in Sickle Cell Patients (BMT CTN 1507)
• A Blood Stem Cell Transplant for Sickle Cell Disease
• A Phase - IIa - IIb, Trial to Study the Safety, Tolerability and Efficacy of Memantine as a Long-term Treatment of SCD
• Peripheral Blood Stem Cell Collection for Sickle Cell Disease (SCD) Patients
• Nonmyeloablative Stem Cell Transplant in Children With Sickle Cell Disease and a Major ABO-Incompatible Matched Sibling Donor
• Enhancing Preventive Therapy of Malaria In Children With Sickle Cell Anemia in East Africa (EPiTOMISE)
• A Study to Evaluate Safety, Pharmacokinetic, and Biological Activity of INCB059872 in Subjects With Sickle Cell Disease
• Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
• Optimizing Hydroxyurea Therapy in Children With SCA In Malaria Endemic Areas
• A Study to Compare if the Uptake of Ticagrelor in the Body Differs When Different Tablets Are Administered
• Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease
• Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease
• An Extension Study to Further Evaluate the Safety, Tolerability of GBT440 in Patients With Sickle Cell Disease Who Participated in the Study GBT440-001
• Study to Evaluate the Effect of Voxelotor Administered Orally to Patients With Sickle Cell Disease (GBT_HOPE)
• Hydroxyurea Management in Kids: Intensive Versus Stable Dosage Strategies
• A Phase Ib Study of NVX-508 in Sickle Cell Disease
• A Study of IMR-687 in Healthy Adult Volunteers
• Pilot and Feasibility Trial of Plerixafor for Hematopoietic Stem Cell (HSC) Mobilization in Patients With Sickle Cell Disease Pilot and Feasibility Trial of Plerixafor for Hematopoietic Stem Cell (HSC) Mobilization in Patients With Sickle Cell Disea
• Fetal Hemoglobin Induction Treatment Metformin
• Dose-Finding Study of SC411 in Children With Sickle Cell Disease
• Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Pediatric and Young Adult Patients With Sickle Cell Anemia
• Macrolide Therapy to Improve Forced Expiratory Volume in 1 Second in Adults With Sickle Cell Disease
• Omega-3 Fatty Acids in Sickle Cell Disease
• Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease
• Topical Sodium Nitrite in Sickle Cell Disease and Leg Ulcers
• Study to Evaluate the Effect of GBT440 in Pediatrics With Sickle Cell Disease
• Mobile-Directly Observed Therapy on Adherence to Hydroxyurea
• Cerebrovascular Reserve Measurements in Sickle Cell Disease
• Ketamine as an Adjuvant Therapy for Acute Vaso Occlusive Crisis in Pediatric Patients With Sickle Cell Disease
• HLA-Identical Sibling Donor Bone Marrow Transplantation for Individuals With Severe Sickle Cell Disease Using a Reduced Intensity Conditioning Regimen
• SACRED A Prospective Research Study to Reduce Stroke in Children With Sickle Cell Anemia
• Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503)
• Transplantation Using Reduced Intensity Approach for Patients With Sickle Cell Disease From Mismatched Family Donors of Bone Marrow
• Rejuvesol® Washed RBC in Sickle Cell Patients Requiring Frequent Transfusions
• The Role of Endothelin-1 in Sickle Cell Disease
• A Phase 1 Study of Continuous Intravenous L-citrulline During Sickle Cell Pain Crisis or Acute Chest Syndrome
• Nonmyeloablative Conditioning for Mismatched Hematopoietic Stem Cell Transplantation for Severe Sickle Cell Disease
• Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease
• Moderate Dose Hydroxyurea for Secondary Stroke Prevention in Children With Sickle Cell Disease in Sub-Saharan Africa
• A Study of SANGUINATE for the Treatment of Vaso-occlusive Crisis (VOC) in Adult Sickle Cell Disease Patients
• A Study of Oral L-citrulline in Sickle Cell Disease
• Macitentan in Pulmonary Hypertension of Sickle Cell Disease
• Desmopressin as a Therapy for Bedwetting in Children With Sickle Cell Disease
• A Multi-Center Study of Riociguat in Patients With Sickle Cell Diseases
• A Pilot Study of Azithromycin Prophylaxis for Acute Chest Syndrome in Sickle Cell Disease
• Clinical Trial to Study the Safety and Tolerability of Memantin Mepha® in Sickle Cell Disease Patients
• A Sickle CEll Disease ComplicatioN Trial
• Contraception in Women With Sickle Cell Disease
• Sub-dissociative Intranasal Ketamine for Pediatric Sickle Cell Pain Crises
• A Single-Dose Relative Bioavailability Study Of GBT440 300 mg Capsules in Healthy Subjects
• Drug Interaction Study of GBT440 With Caffeine, S-warfarin, Omeprazole, and Midazolam in Healthy Subjects
• Primary Prevention of Stroke in Children With SCD in Sub-Saharan Africa II
• EXTEND EXpanding Treatment for Existing Neurological Disease
• Arginine Therapy for Sickle Cell Disease Pain
• Evaluation of the Impact of Renal Function on the Pharmacokinetics of SIKLOS ® (DARH)
• European Sickle Cell Disease Cohort - Hydroxyurea
• Sevuparin Infusion for the Management of Acute VOC in Subjects With SCD
• A Study of the Absorption, Metabolism, and Excretion of GBT440 in Healthy Male Subjects
• A Study to Assess the Effect of Ticagrelor in Reducing the Number of Days With Pain in Patients With Sickle Cell Disease
• Evaluation of Repeat Administration of Purified Poloxamer 188
• Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
• Long-term Safety and Efficacy of Ferriprox® in Iron Overloaded Patients With Sickle Cell Disease or Other Anemias
• HSCT For Patients With High Risk Hemoglobinopathies Using Reduced Intensity
• Safety of Rivipansel (GMI-1070) in the Treatment of One or More Vaso-Occlusive Crises in Hospitalized Subjects With Sickle Cell Disease
• Ketamine Infusion for Acute Sickle Cell Crisis in the Emergency Department
• Study of SANGUINATE™ In the Treatment of Sickle Cell Disease Patients With Vaso-Occlusive Crisis
• Dose-Escalation Study of SCD-101 in Sickle Cell Disease
• Preventing Sickle Cell Kidney Disease
• A Dose Escalation Study of Intravenous L-citrulline in Steady-state Sickle Cell Disease
• Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 or 24 Weeks in Genotype 1 or 4 HCV Infected Adults With Sickle Cell Disease
• Therapeutic Response Evaluation and Adherence Trial (TREAT)
• A Study of the Safety, Blood Levels and Biological Effects of GBT440 in Healthy Subjects and Subjects With Sickle Cell Disease
• Assessment of Algorithm-Based Hydroxyurea Dosing on Fetal Hemoglobin Response, Acute Complications, and Organ Function in People With Sickle Cell Disease
• Comparing Acute Pain Management Protocols for Patients With Sickle Cell Disease
• A Pharmacokinetic (PK) and Pharmacodynamic (PD) Dose-ranging Phase II Study of Ticagrelor in Paediatric Patients With Sickle Cell Disease
• Assessment of Tolerance of Mobilizing Peripheral Hematopoietic Stem Cells by Plerixafor in Sickle Cell Patients
• Escalation of Plerixafor for Mobilization of CD34+ Hematopoietic Progenitor Cells and Evaluation of Globin Gene Transfer in Patients With Sickle Cell Disease
• Inhaled Corticosteroid Use to Prevent Acute Chest Syndrome Recurrence in Children Between 1 and 4 With Sickle Cell Disease: a Feasibility Trial
• Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-Occlusive Crisis in Hospitalized Subjects With Sickle Cell Disease
• Hematopoietic Stem Cell Transplant for High Risk Hemoglobinopathies
• Apixaban in Patients With Sickle Cell Disease
• Haploidentical Hematopoietic Stem Cell Transplantation
• Study of Beet Juice for Patients With Sickle Cell Anemia
• A Study Evaluating the Safety and Efficacy of LentiGlobin BB305 Drug Product in β-Thalassemia Major (Also Referred to as Transfusion-dependent β-Thalassemia [TDT]) and Sickle Cell Disease
• Risk Clinical Stratification of Sickle Cell Disease in Nigeria, Assessment of Efficacy/Safety of Hydroxyurea Treatment
• Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Study Of PF-04447943, Co-Administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease
• Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure
• Feasibility Study of Unfractionated Heparin in Acute Chest Syndrome
• Risk-based Therapy for Sickle Cell Anemia: A Feasibility Study
• The Effect of Rivaroxaban in Sickle Cell Disease
• Safety Study of Gene Modified Donor T-cells Following TCR Alpha Beta Depleted Stem Cell Transplant
• Hematopoietic Stem Cell Transplant for Sickle Cell Disease
• Inhaled Mometasone to Reduce Painful Episodes in Patients With Sickle Cell Disease
• Novel Dose Escalation to Predict Treatment With Hydroxyurea
• Efficacy and Safety of Ferriprox® in Patients With Sickle Cell Disease or Other Anemias
• SCD-Haplo: Phase II Study of HLA-Haploidentical SCT for Aggressive SCD
• Propanolol and Red Cell Adhesion Non-asthmatic Children Sickle Cell Disease
• Losartan for Sickle Cell Kidney Disease
• Evaluation of Different Dose Regimens of Aes-103 Given for 28 Days to Subjects With Stable Sickle Cell Disease
• Novel Use Of Hydroxyurea in an African Region With Malaria
• Realizing Effectiveness Across Continents With Hydroxyurea (REACH)
• Phase 2 Study of Montelukast for the Treatment of Sickle Cell Anemia
• Pain Management in Children and Young Adults With Sickle Cell Disease
• Androgen Regulation of Priapism in Sickle Cell Disease
• Abciximab (ReoPro) as a Therapeutic Intervention for Sickle Cell Vaso-Occlusive Pain Crisis
• Phase 2 Study of MP4CO to Treat Vaso-occlusive Sickle Crisis
• Bone Marrow Transplant With Abatacept for Non-Malignant Diseases
• Quantifying the Presence of Lung Disease and Pulmonary Hypertension in Children With Sickle Cell Disease
• Study to Assess Safety and Impact of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Pain Crises
• Efficacy, Safety Study and Benefit of Alkali Therapy in Sickle Cell Disease
• Nitrous Oxide Analgesia Vaso-occlusive Crisis
• Stem Cell Transplantation for Sickle Cell Anemia
• Non-Myeloablative Conditioning and Bone Marrow Transplantation
• N-Acetylcysteine in Patients With Sickle Cell Disease
• Study of SANGUINATE™ Versus Hydroxyurea in Sickle Cell Disease (SCD) Patients
• Absorption, Metabolism, and Excretion of a Single Dose of Ferriprox® in Patients With Sickle Cell Disease
• Sickle Cell Disease - Stroke Prevention in Nigeria Trial
• A Pilot Study of N-acetylcysteine in Patients With Sickle Cell Disease
• Arginine Therapy in Sickle Cell Disease-VOC Clinical Trial
• A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)
• A Phase II Trial of Regadenoson in Sickle Cell Anemia
• Pediatric Hydroxyurea Phase III Clinical Trial (BABY HUG) Follow-up Observational Study II Protocol
• Safety, Pharmacokinetic, and Pharmacodynamic Study of NKTT120 in Adult Patients With Stable Sickle Cell Disease (SCD)
• Vaporized Cannabis for Chronic Pain Associated With Sickle Cell Disease
• Intravenous Gammaglobulin for Sickle Cell Pain Crises
• Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC)
• Effect of Atorvastatin on Endothelial Dysfunction and Albuminuria in Sickle Cell Disease
• Vascular Function Intervention Trial in Sickle Cell Disease
• Quality of Life Study for Sickle Cell Patients Treated With Jobelyn (Sorghum Bicolor Extract)
• The Efficacy of Jobelyn (Sorghum Bicolor Extract)in the Treatment of Sickle Cell Anemia
• Effect of Simvastatin Treatment on Vaso-occlusive Pain in Sickle Cell Disease
• Study of Decitabine and Tetrahydrouridine (THU) in Patients With Sickle Cell Disease
• Future of Spermatogenesis in Men With Sickle Cell Disease Medically Treated
• Effects of HQK-1001 in Patients With Sickle Cell Disease
• A Single Dose Study of the Safety, Blood Levels and Biological Effects of Aes-103 Compared to Placebo in Subjects With Stable Sickle Cell Disease
• Allogeneic SCT of NiCord®, UCB-Derived Ex Vivo Expanded Stem and Progenitor Cells, in Patients With Hemoglobinopathies
• Imatinib and Carvedilol for High Blood Pressure in the Lungs in Adults With Sickle Cell Disease
• Microvascular Blood Flow in Sickle Cell Anemia
• Bone Marrow Transplantation in Young Adults With Severe Sickle Cell Disease
• Sparing Conversion to Abnormal TCD (Transcranial Doppler) Elevation (SCATE)
• Study to Determine the Maximum Tolerated Dose, Safety and Effectiveness of Pomalidomide for Patients With Sickle Cell Disease
• A Study of Varespladib Infusion in Subjects With Sickle Cell Disease.
• Study Of Efficacy,Safety of Combined Deferasirox and Deferiprone Versus Combined Deferiprone and Desferal In Conditions of Iron Overload
• Pharmacokinetics (PK) of Liquid Hydroxyurea in Pediatric Patients With Sickle Cell Anemia
• Ph I/II Study of Allogeneic SCT for Clinically Aggressive Sickle Cell Disease (SCD)
• Intranasal Fentanyl for Initial Treatment of a Vaso-occlusive Crisis
• Losartan to Reverse Sickle Nephropathy
• A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease
• Haplo T-Cell Depleted Transplantation in High-Risk Sickle Cell Disease
• Vitamin D for Sickle-cell Respiratory Complications
• A Relative Bioavailability Study of a Prasugrel Orally Disintegrating Tablet
• Transcranial Doppler (TCD) With Transfusions Changing to Hydroxyurea
• Treatment of Sickle Cell Patients Hospitalized in Pain Crisis With Prophylactic Dose Low-molecular-weight Heparin (LMWH) Versus Placebo
• Ameliorating Attention Problems in Children With Sickle Cell Disease (SCD)
• Hydroxyurea to Prevent Brain Injury in Sickle Cell Disease
• Choosing Opioid Management for Pain and Analyzing Acute Chest Syndrome (ACS) Rates Equally
• Decitabine for High-Risk Sickle Cell Disease
• Safety Study of MP4CO in Adult Sickle Cell Patients
• Treatment of Sickle Cell Anemia With Stem Cell Transplant
• Vitamin D for Sickle Cell
• A Study of HQK-1001 in Patients With Sickle Cell Disease
• Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation
• Intermittent Preventive Treatment for Malaria in Patient With Sickle Cell Disease
• Topical Sodium Nitrite for Chronic Leg Ulcers in Adult Patients With Blood Disorders
• A Reduced Toxicity Allogeneic Unrelated Donor Stem Cell Transplantation (SCT) for Severe Sickle Cell Disease
• Study of Vitamin D in Children With Sickle Cell Disease
• Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
• Intravenous Magnesium for Sickle Cell Vasoocclusive Crisis
• Albuminuria Reduction With Renin Angiotensin System Inhibitors in SCA Patients
• A Phase III Safety and Efficacy Study of L-Glutamine to Treat Sickle Cell Disease or Sickle βo-thalassemia
• An Assessment of Prasugrel on Healthy Adults and Sickle Cell Adults
• Prasugrel Versus Placebo in Adult Sickle Cell Disease
• L-Arginine and Sickle Cell Disease
• Trial of Zileuton CR in Children and Adults With Sickle Cell Disease
• Study of GMI-1070 for the Treatment of Sickle Cell Pain Crisis
• Angiotensin-converting Enzyme Inhibitors and Early Sickle Cell Renal Disease in Children
• Evaluation of the Safety, Tolerability, Pharmacokinetics (PK) and Effects on Liver Iron Concentration of ICL670 Relative to Deferoxamine(DFO).
• Nitric Oxide Therapy for Acute Chest Syndrome in Sickle Cell Disease Children
• Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease
• Study of Propranolol as Anti-Adhesive Therapy in Sickle Cell Disease (SCD)
• Antioxidant Therapy to Reduce Inflammation in Sickle Cell Disease
• CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant
• Glutamine Therapy for Hemolysis-Associated Pulmonary Hypertension
• Anticoagulation For Pulmonary Hypertension in Sickle Cell Disease
• Safety and Efficacy of Sodium Nitrite in Sickle Cell Disease
• Efficacy of Vorinostat to Induce Fetal Hemoglobin in Sickle Cell Disease
• Clinical Importance of Treating Iron Overload in Sickle Cell Disease
• Haploidentical PBMC Transplant for Severe Congenital Anemias
• Sickle Cell Disease Conditioning for Bone Marrow Transplant
• Sildenafil for Treatment of Priapism in Men With Sickle Cell Anemia
• Endothelial Function in Patients With Sickle Cell Anemia Before and After Sildenafil
• Study of Intravenous GMI-1070 in Adults With Sickle Cell Disease
• Ibuprofen and Opioid (Morphine or Diamorphine) for Acute Pain in Sickle Cell Disease - Sickle With Ibuprofen & Morphine
• Effectiveness of New Analgesic Strategy Compared to the Usal Antalgic Strategy
• Phase 1/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HQK-1001 Administered Daily in Patients With Sickle Cell Disease
• A Safety Study of Eptifibatide in Patients With Sickle Cell Disease
• Inflammatory Response to Hydroxyurea Therapy in Sickle Cell Disease
• TRF-1101 Assessment in Sickle Cell Disease
• Methadone in Pediatric and Adult Sickle Cell Patients
• Pilot Study for Patients With Poor Response to Deferasirox
• Effect of Inhaled Nitric Oxide in Acute Chest Syndrome (INOSTA Study)
• Comparison of Patient Controlled Analgesia (PCA) Versus Bolus Narcotic Therapy for the Treatment of Vaso-Occlusive Crisis (VOC)
• Phase 1 Study of Zoledronic Acid in Sickle Cell Disease
• Ranibizumab for Neovascularization in Sickle Cell Retinopathy
• Low-Dose Ketamine Infusion for Children With Sickle Cell Disease-Related Pain
• L-Glutamine Therapy for Sickle Cell Anemia
• Bone Marrow Transplantation, Hemoglobinopathies, SCALLOP
• Tadalafil for Treatment of Priapism in Men With Sickle Cell Anemia
• Hydroxyurea and Magnesium Pidolate to Treat People With Hemoglobin Sickle Cell Disease
• Dexamethasone to Treat Acute Chest Syndrome in People With Sickle Cell Disease
• Hydroxyurea in Young Children With Sickle Cell Anemia
• Assessment of Opioid Analgesia in Sickle Cell
• Effectiveness of Arginine as a Treatment for Sickle Cell Anemia
• Niacin to Improve Blood Flow in People With Sickle Cell Disease
• Simvastatin (Zocor) Therapy in Sickle Cell Disease
• Sildenafil Therapy for Pulmonary Hypertension and Sickle Cell Disease
• Non-Myeloablative Bone Marrow Transplant for Patients With Sickle Cell Anemia and Other Blood Disorders
• A Phase 2 Study of the Effects of 6R-BH4 in Subjects With Sickle Cell Disease
• IMPACTS Trial: Investigation of the Modulation of Phospholipase in Acute Chest Syndrome
• Stem Cell Transplant in Sickle Cell Disease and Thalassemia
• Hydroxyurea to Prevent Stroke in Children With Sickle Cell Anemia and Elevated TCD Flow Velocity
• Sulfadoxine- Pyrimethamine Versus Weekly Chloroquine for Malaria Prevention in Children With Sickle Cell Anemia
• A Study of Patients Having Pulmonary Hypertension Associated With Sickle Cell Disease and Completing an ASSET Study
• Hydroxyurea for Children and Young Adults With Sickle Cell Disease and Pulmonary Hypertension
• PK and PD Responses to Oral L-Citrulline in Patients With Sickle Cell Disease
• MAST - Magnesium for Sickle Cell Acute Crisis in Children
• Efficacy and Safety of Bosentan in Sickle Cell Disease (SCD) Patients Diagnosed With Pulmonary Hypertension (PH)
• Efficacy and Safety of Bosentan in Sickle Cell Disease (SCD) Patients With Pulmonary Arterial Hypertension (PAH)
• A Study Evaluating the Long-Term Safety of ICA-17043 in Sickle Cell Disease Patients With or Without Hydroxyurea Therapy
• Dipyridamole/Magnesium To Improve Sickle Cell Hydration
• Hydroxyurea and Erythropoietin to Treat Sickle Cell Anemia
• Steroid Treatment for Sickle Cell Pain Crisis
• Pilot Study on the Effects of Intravenous Ketamine on Acute Pain Crisis in Patients With Sickle Cell Disease
• Extension Study of ACTIQ Treatment for Children and Adolescents With Breakthrough Pain
• Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload
• Stem Cell Transplantation With Identical Donors for Patients With Sickle Cell Disease
• Aspirin Prophylaxis in Sickle Cell Disease
• Stem Cell Transplant for Hemoglobinopathy
• Codeine in Sickle Cell Disease
• Allogeneic Stem Cell Transplantation Following Chemotherapy in Patients With Hemoglobinopathies
• Haploidentical Stem Cell Transplant for Patients With Sickle Cell Disease and Prior Stroke or Abnormal Transcranial Ultrasound
• Use of Hydroxyurea and Magnesium Pidolate for Treatment of Sickle Cell Disease
• Inhaled Nitric Oxide for Pediatric Painful Sickle Crisis
• Trial of Oral Glutamine in Patients With Sickle Cell Anemia
• L-Glutamine Therapy for Sickle Cell Anemia and Sickle ß0 Thalassemia
• Stroke With Transfusions Changing to Hydroxyurea
• Ketorolac Versus Ibuprofen to Treat Painful Episodes of Sickle Cell Disease
• Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients
• A Stratified Sickle Event Randomized Trial (ASSERT)
• Therapeutic Application of Intravascular Nitrite for Sickle Cell Disease
• Nitric Oxide Inhalation to Treat Sickle Cell Pain Crises
• Atorvastatin Therapy to Improve Endothelial Function in Sickle Cell Disease
• Safety of ICL670 vs. Deferoxamine in Sickle Cell Disease Patients With Iron Overload Due to Blood Transfusions
• Improving the Results of Bone Marrow Transplantation for Patients With Severe Congenital Anemias
• Evaluation of Hydroxyurea Plus L-arginine or Sildenafil to Treat Sickle Cell Anemia
• Hospital-Based Program for Treatment of Severe Cardiopulmonary Disease With Inhaled Nitric Oxide
• A Study of the Efficacy and Safety of ICA-17043 (With or Without Hydroxyurea) in Patients With Sickle Cell Anemia.
• Bone Marrow Transplant From Related Donor for Patients With High Risk Hemoglobinopathies
• Bone Marrow Transplant From Donor Using Less Toxic Conditioning for Patient With High Risk Hemoglobinopathies
• Stem Cell Transplantation After Reduced-Dose Chemotherapy for Patients With Sickle Cell Disease or Thalassemia
• Arginine Treatment of Acute Chest Syndrome (Pneumonia) in Sickle Cell Disease Patients
• Induction of Stable Chimerism for Sickle Cell Anemia
• Cord Blood Transplantation for Sickle Cell Anemia and Thalassemia
• Nitric Oxide and Transfusion Therapy for Sickle Cell Patients With Pulmonary Hypertension
• Nitric Oxide to Improve Blood Flow in Sickle Cell Disease
• Hydroxyurea to Prevent Organ Damage in Children With Sickle Cell Anemia
• Study of Allogeneic Bone Marrow Transplantation Using Matched, Related Donors in Patients With Nonmalignant Hematologic Disorders
• A Phase I/II Trial of Recombinant-Methionyl Human Stem Cell Factor (SCF) in Adult Patients With Sickling Disorders
• Pilot Study of Fructose for Sickle Cell Crisis
• Phase I/II Randomized Study of Hydroxyurea With or Without Clotrimazole in Patients With Sickle Cell Anemia
• Bone Marrow Transplantation in Treating Children With Sickle Cell Disease
• Phase II Randomized Trial:Arginine Butyrate Plus Standard Local Therapy in Patients With Refractory Sickle Cell Ulcers
• Phase III Randomized Study of Poloxamer 188 for Vaso-Occlusive Crisis of Sickle Cell Disease
• Study of Clotrimazole and Hydroxyurea in Patients With Sickle Cell Syndromes
• Allogeneic Mixed Chimerism Stem Cell Transplant Using Campath for Hemoglobinopathies & Bone Marrow Failure Syndromes
• Effects of Nitric Oxide and Nitroglycerin in Patients With Sickle Cell Anemia
• Hydroxyurea for the Treatment of Patients With Sickle Cell Anemia
• Pediatric Hydroxyurea in Sickle Cell Anemia (PED HUG)
• Multicenter Study of Hydroxyurea in Patients With Sickle Cell Anemia (MSH)
• Penicillin Prophylaxis in Sickle Cell Disease (PROPS)